Figure 8.

Combination therapy with Maraviroc and YM101 induced alterations in the TME and boosted the expression of antitumor immunity‐related genes in the EMT‐6 model. a) The principal component analysis shows the similarities of different groups. b,c) The heatmap displays differentially expressed genes among the four groups, with a focus on immune‐killing genes such as Ifng, Tnf, and Gzmb, which were quantitatively assessed (n = 4). d) Gene Ontology (GO) and KEGG enrichment analysis highlighting significantly enriched biological processes and signaling in the Maraviroc combined with the YM101 group. e–h) Scores of immune signatures, presented as heatmaps showing the scaled expression levels of genes composing immune signatures. Statistical analyses were performed using Student's t‐test (c,e–h). ^* p < 0.05, ^** p < 0.01, ^*** p < 0.001, ^**** p < 0.0001 indicate significant differences compared to the Maraviroc combined with YM101 group.